Efinaconazole (trade names Jublia and Clenafin) is a triazole antifungal. It is approved for use in Canada and the USA, JAPAN as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail).

Property Value
dbo:abstract
  • Efinaconazole (trade names Jublia and Clenafin) is a triazole antifungal. It is approved for use in Canada and the USA, JAPAN as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail). Efinaconazole acts as a 14α-demethylase inhibitor.In two clinical trials 17.8% and 15.2% of patients using efinaconazole were cured, compared to 3.3% and 5.5% of patients using a placebo.Efinaconazole is not especially effective, but it is currently the best topical treatment available, with cure rates two or three times better than the next best topical treatment, ciclopirox. It is considered a reasonable option for patients with mild cases, or patients who can not take oral treatment.In 2014, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for Jublia, the "first topical triazole approved for the treatment of onychomycosis of the toenails." According to Valeant Pharmaceuticals International Inc CEO J. Michael Pearson they acquired Jublia through their purchase of Dow Pharmaceutical Sciences in 2008. (en)
dbo:alternativeName
  • Jublia, Clenafin (en)
dbo:casNumber
  • 164650-44-6
dbo:chEBI
  • 82718
dbo:kegg
  • D10021
dbo:pubchem
  • 489181
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2017-05-09 14:44:55Z (xsd:date)
  • 2017-09-29 12:07:25Z (xsd:date)
  • 2018-04-29 18:15:31Z (xsd:date)
  • 2019-03-27 18:18:38Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 42636927 (xsd:integer)
dbo:wikiPageLength
  • 4666 (xsd:integer)
  • 5066 (xsd:integer)
dbo:wikiPageModified
  • 2017-06-14 01:08:26Z (xsd:date)
  • 2019-03-27 18:11:44Z (xsd:date)
dbo:wikiPageOutDegree
  • 15 (xsd:integer)
dbo:wikiPageRevisionID
  • 785526542 (xsd:integer)
  • 889748904 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:atcPrefix
  • D01 (en)
dbp:atcSuffix
  • AC19 (en)
dbp:bioavailability
  • Unknown (en)
dbp:c
  • 18 (xsd:integer)
dbp:casNumber
  • 164650 (xsd:integer)
dbp:chebi
  • 82718 (xsd:integer)
dbp:chemspiderid
  • 428538 (xsd:integer)
dbp:f
  • 2 (xsd:integer)
dbp:h
  • 22 (xsd:integer)
dbp:iupacName
  • -2 (xsd:integer)
dbp:kegg
  • D10021 (en)
dbp:legalCa
  • Rx-only (en)
dbp:legalUs
  • Rx-only (en)
dbp:licenceUs
  • Efinaconazole (en)
dbp:molecularWeight
  • 348.390000 (xsd:double)
dbp:n
  • 4 (xsd:integer)
dbp:o
  • 1 (xsd:integer)
dbp:pubchem
  • 489181 (xsd:integer)
dbp:routesOfAdministration
  • Topical (en)
dbp:smiles
  • C[C@H]N3CCCCC3 (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • NFEZZTICAUWDHU-RDTXWAMCSA-N (en)
dbp:tradename
  • Jublia, Clenafin (en)
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Efinaconazole (trade names Jublia and Clenafin) is a triazole antifungal. It is approved for use in Canada and the USA, JAPAN as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail). (en)
rdfs:label
  • Efinaconazole (en)
owl:sameAs
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of